Overview

Study of Secukinumab With 2 mL Pre-filled Syringes

Status:
Completed
Trial end date:
2018-06-08
Target enrollment:
Participant gender:
Summary
The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal